Image-based dosimetry for [
225Ac
Dosimetry
PSMA
SPECT
Targeted alpha therapy
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
21 Mar 2024
21 Mar 2024
Historique:
received:
29
09
2023
accepted:
10
03
2024
medline:
21
3
2024
pubmed:
21
3
2024
entrez:
21
3
2024
Statut:
aheadofprint
Résumé
Although Five patients (7.7 ± 0.2 MBq [ Mean kidney and lesion effective half-lives were as follows: SPECT/CT imaging and urine analysis showed minor differences of up to 10% in the daughter-specific pharmacokinetics. These variances had a minimal impact on the lesion and kidney dosimetry which remained within 8%.
Identifiants
pubmed: 38512484
doi: 10.1007/s00259-024-06681-2
pii: 10.1007/s00259-024-06681-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : 02NUK065C
Organisme : Deutsche Forschungsgemeinschaft
ID : EXC 2145 SyNergy - ID 390857198
Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58(10):1624–31.
doi: 10.2967/jnumed.117.191395
pubmed: 28408529
Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, et al. Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving (225)Ac-PSMA-617 radioligand therapy. J Nucl Med. 2020;61(1):62–9.
doi: 10.2967/jnumed.119.229229
pubmed: 31101746
Zacherl MJ, Gildehaus FJ, Mittlmeier L, Boning G, Gosewisch A, Wenter V, et al. First clinical results for PSMA-targeted alpha-therapy using (225)Ac-PSMA-I&T in advanced-mCRPC patients. J Nucl Med. 2021;62(5):669–74.
doi: 10.2967/jnumed.120.251017
pubmed: 33008928
Rosar F, Hau F, Bartholoma M, Maus S, Stemler T, Linxweiler J, et al. Molecular imaging and biochemical response assessment after a single cycle of [(225)Ac]Ac-PSMA-617/[(177)Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [(177)Lu]Lu-PSMA-617 monotherapy. Theranostics. 2021;11(9):4050–60.
doi: 10.7150/thno.56211
pubmed: 33754047
pmcid: 7977444
Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(1):42–51.
doi: 10.1007/s00259-015-3174-7
pubmed: 26318602
Tranel J, Palm S, Graves SA, Feng FY, Hope TA. Impact of radiopharmaceutical therapy ((177)Lu, (225)Ac) microdistribution in a cancer-associated fibroblasts model. EJNMMI Phys. 2022;9(1):67.
doi: 10.1186/s40658-022-00497-5
pubmed: 36178531
pmcid: 9525486
Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57(12):1941–4.
doi: 10.2967/jnumed.116.178673
pubmed: 27390158
Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, et al. Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59(5):795–802.
doi: 10.2967/jnumed.117.203539
pubmed: 29326358
Delker A, Schleske M, Liubchenko G, Berg I, Zacherl MJ, Brendel M, et al. Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging. Eur J Nucl Med Mol Imaging. 2023;50(5):1280–90.
doi: 10.1007/s00259-022-06092-1
pubmed: 36629878
pmcid: 10027798
Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51(2):311–28.
doi: 10.2967/jnumed.108.058651
pubmed: 20080889
Rumiantcev M, Li WB, Lindner S, Liubchenko G, Resch S, Bartenstein P, et al. Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS. EJNMMI Phys. 2023;10(1):53.
doi: 10.1186/s40658-023-00567-2
pubmed: 37695374
pmcid: 10495309
Robertson AKH, Ramogida CF, Rodríguez-Rodríguez C, Blinder S, Kunz P, Sossi V, et al. Multi-isotope SPECT imaging of the 225Ac decay chain: feasibility studies. Phys Med Biol. 2017;62(11):4406.
doi: 10.1088/1361-6560/aa6a99
pubmed: 28362640
Thijssen L, Schaart DR, de Vries D, Morgenstern A, Bruchertseifer F, Denkova AG. Polymersomes as nano-carriers to retain harmful recoil nuclides in alpha radionuclide therapy: a feasibility study. Radiochimica Acta. 2012;100(7):473–82.
doi: 10.1524/ract.2012.1935
Kruijff RM, Raave R, Kip A, Molkenboer-Kuenen J, Morgenstern A, Bruchertseifer F, et al. The in vivo fate of (225)Ac daughter nuclides using polymersomes as a model carrier. Sci Rep. 2019;9(1):11671.
doi: 10.1038/s41598-019-48298-8
pubmed: 31406320
pmcid: 6690960
de Kruijff RM, Drost K, Thijssen L, Morgenstern A, Bruchertseifer F, Lathouwers D, et al. Improved (225)Ac daughter retention in InPO(4) containing polymersomes. Appl Radiat Isot. 2017;128:183–9.
doi: 10.1016/j.apradiso.2017.07.030
pubmed: 28734193
Schwartz J, Jaggi JS, O’Donoghue JA, Ruan S, McDevitt M, Larson SM, et al. Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Phys Med Biol. 2011;56(3):721–33.
doi: 10.1088/0031-9155/56/3/012
pubmed: 21220845
pmcid: 3034478
Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, et al. (2)(1)(3)Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41(11):2106–19.
doi: 10.1007/s00259-014-2857-9
pubmed: 25070685
pmcid: 4525192
Usmani S, Rasheed R, Al kandari F, Marafi F, Naqvi SAR. 225Ac Prostate-specific membrane antigen posttherapy α imaging: comparing 2 and 3 photopeaks. Clin Nucl Med. 2019;44(5):401–3.
Rasheed R, Usmani S, Naqvi SAR, Alkandari F, Marafi F. Alpha therapy with (225)actinium labeled prostate specific membrane antigen: reporting new photopeak of 78 kilo-electron volts for better image statistics. Indian J Nucl Med. 2019;34(1):76–7.
doi: 10.4103/ijnm.IJNM_115_18
pubmed: 30713391
pmcid: 6352636
Benabdallah N, Scheve W, Dunn N, Silvestros D, Schelker P, Abou D, et al. Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes. Theranostics. 2021;11(20):9721–37.
doi: 10.7150/thno.63860
pubmed: 34815780
pmcid: 8581409
Vatsa R, Sood A, Vadi SK, Das CK, Kaur K, Parmar M, et al. 225Ac-PSMA-617 radioligand posttherapy imaging in metastatic castrate-resistant prostate cancer patient using 3 photopeaks. Clin Nucl Med. 2020;45(6):437–8.
doi: 10.1097/RLU.0000000000003031
pubmed: 32366786
Sohlberg A, Watabe H, Iida H. Three-dimensional SPECT reconstruction with transmission-dependent scatter correction. Ann Nucl Med. 2008;22(7):549–56.
doi: 10.1007/s12149-008-0170-z
pubmed: 18756356
Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry–standardization of nomenclature. J Nucl Med. 2009;50(3):477–84.
doi: 10.2967/jnumed.108.056036
pubmed: 19258258
Chauvin M, Borys D, Botta F, Bzowski P, Dabin J, Denis-Bacelar AM, et al. OpenDose: open-access resource for nuclear medicine dosimetry. J Nucl Med. 2020;61(10):1514–9.
doi: 10.2967/jnumed.119.240366
pubmed: 32169912
pmcid: 7539649
Wang G, de Kruijff RM, Rol A, Thijssen L, Mendes E, Morgenstern A, et al. Retention studies of recoiling daughter nuclides of 225Ac in polymer vesicles. Appl Radiat Isot. 2014;85:45–53.
doi: 10.1016/j.apradiso.2013.12.008
pubmed: 24374072
Tichacek CJ, Budzevich MM, Wadas TJ, Morse DL, Moros EG. A Monte Carlo method for determining the response relationship between two commonly used detectors to indirectly measure alpha particle radiation activity. Molecules. 2019;24(18):3397.
Li Z, Fessler JA, Mikell JK, Wilderman SJ, Dewaraja YK. DblurDoseNet: a deep residual learning network for voxel radionuclide dosimetry compensating for single-photon emission computerized tomography imaging resolution. Med Phys. 2022;49(2):1216–30.
doi: 10.1002/mp.15397
pubmed: 34882821
Leube J, Gustafsson J, Lassmann M, Salas-Ramirez M, Tran-Gia J. Analysis of a deep learning-based method for generation of SPECT projections based on a large Monte Carlo simulated dataset. EJNMMI Phys. 2022;9(1):47.
doi: 10.1186/s40658-022-00476-w
pubmed: 35852673
pmcid: 9296746
Ryden T, Van Essen M, Marin I, Svensson J, Bernhardt P. Deep-learning generation of synthetic intermediate projections improves (177)Lu SPECT images reconstructed with sparsely acquired projections. J Nucl Med. 2021;62(4):528–35.
doi: 10.2967/jnumed.120.245548
pubmed: 32859710
pmcid: 8049368